|
|
Livanova Plc (NASDAQ: LIVN) |
|
Price: $35.1800
$0.38 
1.092%
|
| Day's High:
| $35.69
| Week Perf:
| 3.05 %
|
| Day's Low: |
$ 34.00 |
30 Day Perf: |
-12.94 % |
| Volume (M): |
158 |
52 Wk High: |
$ 64.48 |
| Volume (M$): |
$ 5,548 |
52 Wk Avg: |
$49.79 |
| Open: |
$34.13 |
52 Wk Low: |
$32.48 |
|
|
| Market Capitalization (Millions $) |
1,918 |
| Shares
Outstanding (Millions) |
55 |
| Employees |
2,900 |
| Revenues (TTM) (Millions $) |
1,253 |
| Net Income (TTM) (Millions $) |
63 |
| Cash Flow (TTM) (Millions $) |
146 |
| Capital Exp. (TTM) (Millions $) |
47 |
Livanova Plc
Livanova Plc is a diversified medical technology company that is committed to improving patient outcomes and reducing the cost of healthcare in the areas of cardiovascular and neuromodulation treatment. The company was formed in 2015, as a result of a merger between Cyberonics Inc. and Sorin Group.
Headquartered in London, Livanova operates in over 100 countries worldwide, with its primary focus being on the development, manufacture, and marketing of medical devices used in the treatment of various heart and neurological conditions. It has over 3,500 employees working across its various manufacturing and research facilities in the United States, Europe, and Asia-Pacific.
Livanovaes Cardiovascular business segment offers a range of products that include heart-lung equipment, oxygenators, perfusion systems, cannulae, and devices used in extracorporeal membrane oxygenation (ECMO) therapy. Its pioneering ECMO technology is widely recognized and used for treating life-threatening cardiopulmonary failure in neonatal and pediatric patients. The companyes implantable cardiac rhythm management products, including pacemakers, defibrillators, and cardiac resynchronization therapy devices, are designed to manage cardiac arrhythmias and heart failure.
The Neuromodulation business segment of Livanova provides products for the treatment of patients with epilepsy, depression, chronic pain, and other neurological disorders. Its Vagus Nerve Stimulation (VNS) Therapy System is a revolutionary device that delivers electrical stimulation to the vagus nerve, offering relief to patients with epilepsy and depression who have not responded to traditional treatments. The segment also produces Deep Brain Stimulation (DBS) Systems, which can reduce symptoms of movement disorders such as Parkinsones disease.
Livanova Plc is dedicated to research and development, with a strong pipeline of new products and technological innovation. They continually invest in research and development and have a strong focus on profitability and growth. They have a strong corporate culture, and their core values include focusing on patients, working collaboratively, continuous improvement, and maintaining a high level of ethical conduct.
In conclusion, Livanova Plc is a global leader in the development and manufacture of medical technology that improves the lives of people with heart and neurological conditions. With a dedicated team, strong product pipeline, and a commitment to innovation, Livanova is well-positioned to grow in the medical device market for many years to come.
Company Address: 20 Eastbourne Terrace London 0
Company Phone Number: 203 325-0660 Stock Exchange / Ticker: NASDAQ LIVN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Livanova Plc
Livanova Plc Reports Positive Income Growth for Q3 2024, Stock Performance Indicates Confidence in the Company?s RecoveryLondon, United Kingdom - - Livanova Plc, a global medical technology company, has announced a significant turnaround in its financial performance for the fiscal period spanning July to September 30, 2024, posting an income of $0.60 per share, compared to a loss of $-0.14 per share a year earlier. This marks a substantial improvement, reflecting a remarkable recovery trajectory for the company.The latest earnings report reveals that the company achieved a revenue increase of 11.01% year-on-year, bringing total revenue for the recent quarter to $317.26 million, up from $285.80 million in the same period last year. However, the revenue saw a slight sequential decline of -0.19% from $317.87 million in the preceding quarter. Livanova's growth was attributed to strong performance across its diverse business segments. Cardiopulmonary revenue surged by 15.63%, while Neuromodulation revenues increased by 8.52%. Geographically, the United States market showed robust growth, with an 11.29% increase overall, bolstered by a 19.55% rise in Cardiopulmonary sales and a 10.18% boost in Neuromodulation. Europe also performed well, achieving a year-on-year revenue growth of 9.74%, driven by a 15.25% increase in Cardiopulmonary products. Despite the overall positive performance, Livanova reported declines in certain areas, including a substantial 27.28% drop in Other Revenue and a 5.84% decrease in Europe?s Neuromodulation sector. The company reported a bottom-line profit of $32.953 million for the fiscal span, a remarkable improvement compared to a net loss of $-7.318 million a year ago. Livanova also highlighted enhanced profitability metrics, with net margins rising to 10.39% and operating margins edging up to 11.23%. Operating earnings exploded by 698.97% to $35.618 million, showcasing the company?s strong operational efficiency.
|
| Livanova Plc
Livanova Plc, a leading Medical Equipment & Supplies company, recently reported an 11.758% increase in revenue for the first quarter of 2024 compared to the same period last year. This growth outpaced that of its sector peers, who reported an overall 6.18% revenue improvement during the same timeframe. Despite this positive top-line performance, the company reported a loss of $0.78 per share for the quarter.
This news comes as a surprise to many investors, as Livanova Plc had previously shown strong earnings and revenue growth. In the preceding reporting period, the company experienced a decrease in revenue of -5.08% and a drop in earnings per share from $0.29 to -$0.78. This downward trend in financial performance is concerning for shareholders and analysts alike.
|
| Livanova Plc
Livanova Plc, a leading company in the Medical Equipment & Supplies sector, has reported impressive financial results for the period closing on December 31, 2023. The company witnessed a significant increase in its income per share, which soared by an impressive 859.07% to $0.29 per share. Furthermore, its revenue experienced a boost of 12.832% to reach $310.15 million, compared to the previous year.
Compared to its competitors in the Medical Equipment & Supplies sector, Livanova Plc's revenue growth was even more remarkable. In the fourth quarter of 2023, most corporations in the sector experienced a 7.86% increase in revenue relative to the same period a year ago. However, Livanova Plc outperformed its contemporaries by achieving a higher revenue growth rate.
|
| Livanova Plc
Interpreting Livanova Plc's recent financial results, it is evident that the company has experienced both positive and negative developments. While the company's revenue increased by an impressive 13.142% to $285.80 million in the September 30, 2023 report compared to the previous year's corresponding reporting season, it was disappointing to see a loss of $-0.14 shortfall per share.
However, it is worth noting that Livanova Plc's revenue growth in the third quarter of 2023 aligns favorably with its counterparts in the Medical Equipment & Supplies sector. The sector as a whole saw a 0.80% increase in top-line performance during the same period. In the previous reporting season, Livanova Plc experienced a decrease in revenue by -2.749% from $293.88 million, and the income per share also declined from $0.02 per share.
|
| Livanova Plc
Livanova Plc, a global medical technology company, recently released its second quarter financial report for 2023. The report revealed a sharp decline in income, while revenue showed substantial growth compared to the same quarter of the previous year. This article will provide an overview and analysis of Livanova Plc's financial performance during this period, as well as contextualize it within the company's current stock market performance.
Financial Results in Q2 2023:
Livanova Plc experienced a significant decline in its bottom-line as income fell sharply by -93.33% to $0.02 per share. However, revenue increased by 15.633% to $293.88 million from the same quarter a year before.
This decline in income was also evident when compared to the previous quarter, with earnings per share (EPS) plummeting by -85.71% from $0.14 to $0.02 per share. Nevertheless, revenue showed growth of 11.565% from $263.42 million.
|
| Per Share |
Current |
| Earnings (TTM) |
1.12 $ |
| Revenues (TTM) |
22.98 $
|
| Cash Flow (TTM) |
2.67 $ |
| Cash |
13.27 $
|
| Book Value |
24.22 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.12 $
|
| Revenues (TTM) |
22.98 $ |
| Cash Flow (TTM) |
2.67 $ |
| Cash |
13.27 $
|
| Book Value |
24.22 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Cardiopulmonary |
|
 54.29 % |
of total Revenue |
| Neuromodulation |
|
44.08 % |
of total Revenue |
| Other Revenue |
|
1.9 % |
of total Revenue |
| United States |
|
56.68 % |
of total Revenue |
| United States Cardiopulmonary |
|
19.7 % |
of total Revenue |
| United States Neuromodulation |
|
35.59 % |
of total Revenue |
| Europe |
|
16.65 % |
of total Revenue |
| Europe Cardiopulmonary |
|
12.89 % |
of total Revenue |
| Europe Neuromodulation |
|
3.76 % |
of total Revenue |
| Rest of World |
|
26.94 % |
of total Revenue |
| Rest of World Cardiopulmonary |
|
21.7 % |
of total Revenue |
| Rest of World Neuromodulation |
|
4.74 % |
of total Revenue |
|
|
3.77% 